Cargando…

A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency

Secondary antibody deficiency (SAD) is a common complication in chronic lymphocytic leukemia (CLL) which favors the development of life-threatening infections. Subcutaneous immunoglobulins (IG) (SCIG) have been proven to be as effective as intravenous immunoglobulin (IVIG) in primary immunodeficienc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Visentin, Andrea, Molinari, Maria Chiara, Pravato, Stefano, Cellini, Alessandro, Angotzi, Francesco, Cavaretta, Chiara Adele, Ruocco, Valeria, Imbergamo, Silvia, Piazza, Francesco, Proietti, Giulia, Mauro, Francesca Romana, Trentin, Livio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857433/ https://www.ncbi.nlm.nih.gov/pubmed/36661671 http://dx.doi.org/10.3390/curroncol30010022

Ejemplares similares

From Biology to Treatment of Monoclonal Gammopathies of Neurological Significance
por: Visentin, Andrea, et al.
Publicado: (2022)

P054: The Kinase CK2 is deregulated and targetable in classical Hodgkin Lymphoma
por: Visentin, Andrea, et al.
Publicado: (2022)

P1075: ADVANCED-STAGE CHL INTERNATIONAL PROGNOSTICATION INDEX: EXTERNAL VALIDATION IN A SINGLE-CENTER RETROSPECTIVE PATIENT DATASET AND COMPARISON TO THE HASENCLEVER IPS
por: Cellini, Alessandro, et al.
Publicado: (2023)

P005: Age, histotype and stage IV are associated with a shorter survival in patients with Hodgkin lymphoma, even the PET-adapted era. A single center retrospective study.
por: Visentin, Andrea, et al.
Publicado: (2022)

Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies
por: Angotzi, Francesco, et al.
Publicado: (2023)

Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies
por: Cinetto, Francesco, et al.
Publicado: (2021)

Tackling the dysregulated immune-checkpoints in classical Hodgkin lymphoma: bidirectional regulations between the microenvironment and Hodgkin/Reed-Sternberg cells
por: Cellini, Alessandro, et al.
Publicado: (2023)

Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases
por: Angotzi, Francesco, et al.
Publicado: (2022)

P1076: A RETROSPECTIVE ANALYSIS ON OLD AND EMERGING PROGNOSTIC FACTORS IN CLASSICAL HODGKIN’S LYMPHOMA IN THE PET-GUIDED ERA
por: Cellini, A., et al.
Publicado: (2022)

Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia
por: Visentin, Andrea, et al.
Publicado: (2020)

Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies
por: Canessa, Clementina, et al.
Publicado: (2016)

Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia
por: Frezzato, Federica, et al.
Publicado: (2021)

Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases
por: Visentin, Andrea, et al.
Publicado: (2017)

Scleromyxedema with Subcutaneous Nodules: Successful Treatment with Thalidomide and Intravenous Immunoglobulin
por: Dolenc-Voljč, M., et al.
Publicado: (2013)

Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study
por: Visentin, Andrea, et al.
Publicado: (2022)

Severe Fatal Mucormycosis in a Patient with Chronic Lymphocytic Leukaemia Treated with Zanubrutinib: A Case Report and Review of the Literature
por: Maggioni, Giuseppe, et al.
Publicado: (2023)

Pneumococcal Antibody Titers: A Comparison of Patients Receiving Intravenous Immunoglobulin Versus Subcutaneous Immunoglobulin
por: Abghari, Pamella F., et al.
Publicado: (2017)

The BCL2 Inhibitor Venetoclax Plus Rituximab Is Active in MYD88 Wild-Type Polyneuropathy With Anti-MAG Antibodies
por: Briani, Chiara, et al.
Publicado: (2022)

Vasculitic flare in a patient with anti-myelin-associated glycoprotein (MAG) antibody following mRNA-1273 SARS-CoV-2 vaccine
por: Briani, Chiara, et al.
Publicado: (2022)

PB2261: LINEZOLID AS A SAFE ANTIMICROBIAL AGENT IN THROMBOCYTOPENIC PATIENTS UNDERGOING CHEMOTHERAPY FOR HEMATOLOGIC MALIGNANCIES
por: Angotzi, F., et al.
Publicado: (2022)

The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation
por: Visentin, Andrea, et al.
Publicado: (2021)

Is It Safe to Switch From Intravenous Immunoglobulin to Subcutaneous Immunoglobulin in Patients With Common Variable Immunodeficiency and Autoimmune Thrombocytopenia?
por: Scheuerlein, Philipp, et al.
Publicado: (2018)

The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia
por: Visentin, Andrea, et al.
Publicado: (2019)

Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
por: Waller, Cornelius F., et al.
Publicado: (2021)

Comment on: “Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients”
por: Visentin, Andrea, et al.
Publicado: (2021)

Mutational Profile in 75 Patients With Anti–Myelin-Associated Glycoprotein Neuropathy: Clinical and Hematologic Therapy Response and Hints on New Therapeutic Targets
por: Castellani, Francesca, et al.
Publicado: (2023)

Switch from intravenous or intramuscular to subcutaneous hepatitis B immunoglobulin: effect on quality of life after liver transplantation
por: Volpes, Riccardo, et al.
Publicado: (2020)

Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide
por: Gallwitz, Baptist, et al.
Publicado: (2021)

Subcutaneous Immunoglobulins are a Valuable Treatment Option in Myasthenia Gravis
por: Garnero, Martina, et al.
Publicado: (2018)

Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada
por: Gerth, William C, et al.
Publicado: (2014)

INTRAVENOUS IMMUNOGLOBULIN IN DERMATOLOGY
por: Dhar, Sandipan
Publicado: (2009)

Effect of Intravenous IgM-Enriched Immunoglobulins on Presepsin and Other Sepsis Biomarkers
por: Scarpati, Giuliana, et al.
Publicado: (2021)

On the Subcutaneous Injection of Blood, Infusion (Subcutaneous) and Intravenous Transfusion
por: Oehler,, et al.
Publicado: (1888)

New Frontiers in Subcutaneous Immunoglobulin Treatment
por: Jolles, Stephen, et al.
Publicado: (2011)

Use of subcutaneous immunoglobulin in inflammatory myositis
por: Zhou, Alan L, et al.
Publicado: (2021)

In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment
por: Severin, Filippo, et al.
Publicado: (2019)

Treatment costs associated with hospital-based intravenous immunoglobulin therapy compared to home-based subcutaneous immunoglobulin therapy in a cohort of paediatric patients with primary immunodeficiency
por: Ducruet, Thierry, et al.
Publicado: (2011)

The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy
por: Castellani, Francesca, et al.
Publicado: (2020)

Efficacy and safety of human intravenous immunoglobulin 5% (Ig VENA) in pediatric patients affected by primary immunodeficiency
por: Ricci, Silvia, et al.
Publicado: (2020)

Subcutaneous Immunoglobulin-G Replacement Therapy with Preparations Currently Available in the United States for Intravenous or Intramuscular Use: Reasons and Regimens
por: Chouksey, Akhilesh, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_avufbq09na2bcrkcm8mkqo6pm3